TIME Names Xenco Medical One of the TIME100 Most Influential Companies in the World and the Winner of the 2026...
Xenco Medical was named one of the 2026 TIME100 Most Influential Companies and received the exclusive TIME100 Impact Award in Health. The accolade follows prior honors such as 2025 Medical Device/Diagnostics Company of the Year, Fast Company’s Most Innovative Companies, and a World Economic Forum governance award. Xenco’s portfolio includes biomimetic implants, regenerative biomaterials, AI‑enabled remote therapeutic monitoring, and holographic surgical simulation, positioning it as a leader in value‑based care. The recognition underscores the company’s global impact on surgical efficiency and patient outcomes.
How Advanced Mammography Viewers Are Shaping the Future of Breast Cancer Detection
Advanced mammography viewers are delivering sharper, lower‑noise images that help radiologists spot cancers, especially in dense breast tissue. Yet the industry’s biggest hurdle is integrating these tools into real‑world workflows, where speed, usability, and system compatibility dictate whether improved visuals...
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
Merck announced the first patient has been dosed in its global Phase 3 ELOWEN program, testing the oral TLR7/8 inhibitor enpatoran in lupus patients with active skin manifestations. The double‑blind, placebo‑controlled studies—ELOWEN‑1 and ELOWEN‑2—will enroll roughly 200 participants each across 266...
Elevance Health’s Affiliated Health Plans Deliver More Predictable, Lower Healthcare Costs for Small Businesses
Elevance Health’s affiliated plans are tackling rising small‑business health costs with two innovative models: Balanced Funding and Multiple Employer Welfare Arrangements (MEWAs). Balanced Funding guarantees a fixed monthly payment while capping risk, rewarding employers when actual claims fall below expectations....
CGT Global Appoints Charlotte Ivancic to Board of Advisors, Strengthening Strategic Leadership in Cell and Gene Therapy Policy and Market...
CGT Global announced the appointment of Charlotte Ivancic to its Board of Advisors, bringing over 25 years of federal health policy and legislative experience. Ivancic, a partner at FGS Global and former senior aide to Senate Majority Leader Bill Frist,...
Prilenia Appoints Dr. Elisabeth Leiderman as Chief Financial Officer
Prilenia Therapeutics announced the appointment of Dr. Elisabeth (Lis) Leiderman, MD, MBA as its new chief financial officer. Leiderman brings over two decades of finance, corporate development, and investment‑banking experience in life sciences, including CFO roles at Dewpoint, Atsena and...
Ludi Announces Ludi Boost™: New AI-Powered Operating Model & Strategic Services Offering for Provider Workforce Management
Ludi, Inc. unveiled Ludi Boost™, an AI‑enabled compensation platform that bundles advanced technology with a strategic services team of more than 80 experts. The solution consolidates compensation data, governance and administration into a single system of record, promising faster program execution,...
Ashvattha Therapeutics Announces Presentations Highlighting Mechanism of Action for Migaldendranib in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
Ashvattha Therapeutics presented Phase 2 data on its subcutaneous nanomedicine migaldendranib (MGB) for diabetic macular edema and neovascular age‑related macular degeneration at ARVO. The two‑stage trial showed stable central subfield thickness for up to 12 weeks and maintained visual acuity without...
AtriCure to Participate in the 2026 Bank of America Securities Health Care Conference
AtriCure announced it will take part in the 2026 Bank of America Securities Health Care Conference, with senior management slated for a fireside chat on May 12, 2026. The session will be streamed live via the company’s investor website, giving...
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-Cel
Cellares has entered a 10‑year commercial supply agreement with Cabaletta Bio to manufacture rese‑cel, the company’s autologous CAR‑T therapy for autoimmune diseases, using its fully automated Cell Shuttle and Cell Q platforms. The deal secures long‑term capacity to produce thousands of...
Superior Health Holdings Acquires Compassion Homecare and Sans Bois Hospice, Expanding Into Oklahoma
Superior Health Holdings, backed by Renovus Capital Partners, announced the acquisition of Chant Healthcare, the operator of Compassion Home Care and Sans Bois Hospice in southeastern Oklahoma. The deal gives Superior an immediate footprint across 11 counties, adding home health, hospice,...
The MolinaCares Accord Provides $100,000 Grant to Lurie Children’s in Support of Statewide School Mental Health Initiative
MolinaCares, the community‑investment arm of Molina Healthcare, has awarded a $100,000 grant to Lurie Children’s Hospital’s Center for Childhood Resilience to support the Resilience‑Supportive Schools Illinois (RSSI) initiative. RSSI equips Illinois schools with data‑driven tools, professional learning, and evidence‑informed resources...
Infinimmune Appoints Anthony Slavin, Ph.D., as Senior Vice President of Portfolio Strategy
Infinimmune announced the appointment of Anthony Slavin, Ph.D., as Senior Vice President of Portfolio Strategy. Slavin will steer the company’s portfolio development, guiding the selection of new antibody programs and advancing its existing pipeline. He arrives with a proven track record...
Samsung Bioepis Releases Second Quarter 2026 US Biosimilar Market Report
Samsung Bioepis released its Q2 2026 U.S. Biosimilar Market Report, the thirteenth edition of the quarterly series. The report documents 92 FDA‑approved biosimilars across 20 molecules, with 67 (73 %) already launched, and notes a 60 % adoption rate for adalimumab biosimilars. It...
Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System
Cerus Corporation announced a four‑year supply agreement with France’s national blood service, Établissement Français du Sang (EFS), for its INTERCEPT Blood System covering platelets, plasma, and the new LED‑based INT200 illumination device. EFS distributes roughly 330,000 platelet units each year...
Mundipharma Announces Positive Topline Results From Phase III ReSPECT Trial Assessing ▼REZZAYO® (Rezafungin) for the Prophylaxis of Invasive Fungal Diseases...
Mundipharma reported that its Phase III ReSPECT trial met the primary endpoint, showing rezafungin (REZZAYO®) was non‑inferior to standard antifungal regimens for fungal‑free survival at Day 90 (60.7% vs 59.0%). The once‑weekly echinocandin demonstrated a comparable safety profile with fewer drug‑drug interactions...
DocGo to Announce First Quarter 2026 Results on Monday, May 11, 2026
DocGo Inc. (Nasdaq: DCGO) announced it will publish its first‑quarter 2026 financial results after market close on Monday, May 11, 2026. The company will host a conference call and webcast at 5:00 p.m. ET to discuss the results. DocGo describes itself...
VVARDIS Announces Investment From Apollo —Achieves Unicorn Status
vVARDIS Holding AG announced a strategic minority investment from Apollo‑managed funds, propelling the Swiss dental‑med tech firm into unicorn status with a valuation north of $1 billion. The capital will finance the next phase of global commercial expansion for its Curodont™...
Qwen AI Glasses Witness Grand Opening of China Intangible Cultural Heritage Crafts Exhibition at Milan Design Week
The China Intangible Cultural Heritage Crafts Exhibition opened at Milan Design Week featuring the world’s first documentary shot with Qwen AI Glasses, an AI‑powered wearable that records from a first‑person perspective. The glasses captured 12‑MP, 3K‑4K video of artisans, offered...
Hippocratic AI Expands Footprint, Partners with Leading Health Systems to Improve Patient Outcomes
Hippocratic AI announced new collaborations with Cincinnati Children’s, UNC Health and the Gift of Life Marrow Registry, extending its safety‑first generative AI tools across pediatrics, primary‑care scheduling and donor outreach. The company’s AI Front Door and Nurse Co‑Pilot are now...
Sonida Senior Living Announces First Quarter Earnings Release Date and Conference Call
Sonida Senior Living announced it will publish its first‑quarter 2026 earnings on Monday, May 11, before the market opens. The results will be followed by a conference call and webcast at 11:00 a.m. Eastern Time. The company, which recently merged...
Frankfurt Higher Regional Court Upholds BESREMi® Arbitral Award in Favor of AOP Health
The Frankfurt Higher Regional Court dismissed PharmaEssentia’s attempt to set aside a February 2025 ICC arbitral award, confirming the award in favor of AOP Health. The award, originally €143 million (about $156 million), stems from PharmaEssentia’s breach of its licensing agreement for...
Sunnybrook Announces $41-Million Gift to Advance Canada’s Global Leadership in Clinical Trials
Sunnybrook Health Sciences Centre announced a $41 million CAD (≈$30 million USD) philanthropic gift to expand its Sunnybrook Clinical Trials program. The funding creates new leadership positions, boosts biobanking, data management and precision diagnostics, and supports first‑time investigators. By strengthening infrastructure and...
Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026
Quanterix Corporation announced it will release its first‑quarter 2026 financial results after the market closes on May 6, 2026, followed by a conference call at 4:30 p.m. ET. The press release and live webcast will be posted on the company’s investor relations site,...
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign
Genentech, part of the Roche Group, launched the "All Eyes on DME" campaign to raise awareness of diabetic macular edema (DME) using humor and personal stories. The initiative partners with comedian Damon Wayans, who lives with type 2 diabetes, and advocacy...
Lantern Pharma to Debut Public Demonstration of withZeta.ai – A Platform to Conquer Rare Cancers on April 30 Following AACR...
Lantern Pharma announced a public, unscripted demonstration of its withZeta.ai AI co‑scientist platform on April 30, 2026. CEO Panna Sharma will lead two live sessions—morning and afternoon ET—to showcase real‑time drug‑discovery workflows for rare cancers. The event follows the platform’s...
Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast
Bruker Corporation announced that it will release its first‑quarter 2026 financial results before the market opens on Wednesday, May 6, 2026, at 8:00 a.m. Eastern Time. The earnings discussion will be streamed live via the company’s investor‑relations website and also available by telephone,...
Bristol Myers Squibb and Pfizer to Make Eliquis® (Apixaban) Available via Mark Cuban Cost Plus Drug Company
Bristol Myers Squibb and Pfizer announced that their joint‑venture will sell Eliquis® (apixaban) through Mark Cuban’s Cost Plus Drugs platform starting April 27, 2026. Cash‑pay patients can purchase a 30‑day supply for $345, a price positioned below many insurance copays. The move expands the...
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
Merck announced that the Hart‑Scott‑Rodino antitrust waiting period for its pending acquisition of Terns Pharmaceuticals expired at 11:59 p.m. ET on April 23, 2026. The company’s cash tender offer, launched on April 7, proposes to buy each Terns share for $53 in cash, less...
Shields Health Solutions Partners with Columbus Regional Health to Enhance Patient Access to Specialty Pharmacy Services
Shields Health Solutions announced a partnership with Columbus Regional Health, its first Indiana health‑system collaborator, to expand specialty pharmacy services. The joint effort will initially support more than 8,000 patients with complex conditions such as cancer, multiple sclerosis, and autoimmune...
Curve Biosciences Announces Key AI and Clinical Advancements of Whole-Body Intelligence for Chronic Diseases
Curve Biosciences announced two major milestones: its genomic AI foundation model will be presented at the International Conference on Learning Representations (ICLR) and its Whole‑Body Blood Test demonstrated strong performance in a real‑world liver cirrhosis monitoring study. The study enrolled...
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
Zai Lab Limited announced it will disclose its first‑quarter 2026 financial results on May 7, 2026, ahead of the U.S. market open. The earnings release will be accompanied by a conference call and webcast at 8:00 a.m. ET, with registration required for...
Nicklaus Children’s Hospital Is First in Region to Offer Sedation-Free Evaluation of Upper Gastrointestinal Tract in Children
Nicklaus Children’s Hospital has become the first South Florida facility to offer sedation‑free transnasal endoscopy (TNE) for pediatric patients, using EvoEndo’s single‑use system. The TNE procedure evaluates the upper gastrointestinal tract without the need for anesthesia, IV lines, or prolonged...
CellCarta Eliminates 9-Hours-Per-Week Regulatory Bottleneck with RegASK’s AI-Driven Intelligence Platform
CellCarta, a global contract research organization, partnered with RegASK to overhaul its regulatory intelligence function. By deploying RegASK’s agentic AI platform, the CRO replaced a manual nine‑hour‑per‑week monitoring process with near‑real‑time updates. The new centralized hub automatically captures, validates and...
Axion BioSystems and Agilent Technologies Resolve Litigation
Axion BioSystems and Agilent Technologies announced a confidential settlement that fully resolves two Delaware lawsuits. Both companies denied liability and agreed to move forward without admitting any claims. The settlement allows Axion to continue manufacturing, marketing, and developing its live‑cell...
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
Agenus appointed BAP Pharma as its exclusive global partner to manage early‑access programs for the botensilimab‑balstilimab (BOT+BAL) immunotherapy combo. The collaboration will handle France’s government‑reimbursed Autorisation d’Accès Compassionnel (AAC) pathway and paid named‑patient programs in several other markets. Agenus has...
Charles River Highlights Effectiveness of VCGs in Toxicology
Charles River Laboratories published a retrospective analysis of 20 nonclinical toxicology studies that replaced traditional concurrent control groups with virtual control groups (VCGs). The review found 100% concordance in No Observed Adverse Effect Level (NOAEL) determinations and demonstrated up to...
Star Therapeutics Receives FDA Rare Pediatric Disease and Breakthrough Therapy Designations for VGA039 in Von Willebrand Disease Prophylaxis
Star Therapeutics announced that the FDA has granted both rare pediatric disease and Breakthrough Therapy designations to its lead candidate VGA039, a monoclonal antibody aimed at preventing bleeding in von Willebrand disease (VWD). The designations support the ongoing Phase 3 VIVID‑6 study,...
BODi Expands GLP-1 Support and Longevity-Driven Fitness with “10 Minute BODi” Workouts
BODi announced three new 10‑Minute BODi digital programs—Speed Train, Active Aging, and GLP‑1 Fitness Formula—expanding its micro‑dose fitness catalog for busy consumers, seniors, and users of GLP‑1 medications. Speed Train adds 22 resistance workouts, Active Aging delivers 15 mobility‑focused sessions...
The AgeTech Collaborative™ From AARP and HLTH Launch Landmark Collaboration to Advance the Future of Aging
HLTH Inc. and AARP’s AgeTech Collaborative have announced a landmark partnership to accelerate aging‑technology startups. The collaboration will feature 20 vetted companies at HLTH 2026 in Las Vegas, giving them exposure to investors, health systems, and industry leaders. Leveraging AARP’s longevity expertise...
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products
Simulations Plus announced a funded collaboration with CDMO Lonza and the U.S. FDA to create a mechanistic, predictive framework for amorphous solid dispersion (ASD) oral drugs. The partnership will combine Lonza's advanced in‑vitro dissolution testing with Simulations Plus' GastroPlus and...
HSS Studies Contribute Early Evidence to Help Guide Emerging Perioperative Considerations for Patients Using GLP‑1 Medications
At the ASRA annual meeting, Hospital for Special Surgery researchers presented two studies on peri‑operative management of patients taking GLP‑1 agonists. A multicenter ultrasound assessment of 354 elective surgery patients found no statistically significant difference in full‑stomach incidence between GLP‑1...
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
Compass Pathways welcomed the White House Executive Order aimed at speeding up research and access to psychedelic therapies for serious mental illness. The biotech highlighted its COMP360 synthetic psilocybin, which has delivered statistically significant results in two Phase 3 trials for...
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation...
Zai Lab unveiled preclinical data for ZL-1503, a bispecific antibody that blocks IL-13 and IL-31Rα, showing sustained itch suppression and inflammation reduction for up to 112 days after a single dose. The study demonstrated dose‑dependent efficacy across skin, lung, nasal...
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product
The U.S. Food and Drug Administration has renewed its Modified Risk Tobacco Product (MRTP) authorizations for Philip Morris International’s IQOS heated‑tobacco system and three HEETS consumable flavors. The renewal covers the IQOS 2.4 and IQOS 3.0 devices, allowing PMI to continue marketing...
Blue Cross Blue Shield of Michigan Postpones Modifier 25 Policy in Response to Osteopathic Advocacy
Blue Cross Blue Shield of Michigan announced a postponement of its proposed modifier 25 reimbursement policy after coordinated advocacy from five osteopathic organizations. The delay aims to preserve accurate billing for evaluation and management services, especially osteopathic manipulative treatment, and to...
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal...
Agenus presented Phase II data showing that a combination of botensilimab, balstilimab and the allo‑iNKT cell therapy agenT‑797 achieved a 77% disease‑control rate in PD‑1‑refractory gastroesophageal adenocarcinoma. Patients who received an induction cycle of agenT‑797 before the full regimen experienced median...
SAGA Diagnostics to Present New Pathlight™ MRD Data for Ovarian and Metastatic Breast Cancer at AACR 2026
SAGA Diagnostics will present two abstracts at AACR 2026 showcasing its Pathlight™ structural‑variant‑based circulating tumor DNA (ctDNA) assay. In metastatic breast cancer, the test achieved a 77% detection rate, with ultrasensitive reads predicting therapeutic response and preceding radiologic progression. In...
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer...
Zai Lab reported that its DLL3‑targeting ADC zocilurtatug pelitecan (Zoci) generated a 53.7% confirmed intracranial objective response rate (iORR) in extensive‑stage small‑cell lung cancer (ES‑SCLC) patients with brain metastases, rising to 62.5% at the 1.6 mg/kg dose. In a separate cohort...
Acerand Therapeutics Updates the Phase I/II Study of ACE-106 (ACE-86225106), a Highly Selective and Potentially Best-in-Class PARP1 Inhibitor, in Advanced...
Acerand Therapeutics reported updated Phase I/II data for ACE‑106, a highly selective PARP1 inhibitor, in 57 heavily pre‑treated patients with advanced solid tumors. The drug showed no dose‑limiting toxicities and a safety profile that appears better than approved PARP inhibitors....